

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION ON THE GROUP'S PRODUCT

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that on 17 April 2023, The United Bio-Technology (Hengqin) Co., Ltd. ("The United Bio-Technology"), a wholly-owned subsidiary of the Company, received the Notice of Approval of Clinical Trial (Reference No.: 2023LP00698 and 2023LP00699) issued by China National Medical Products Administration regarding Semaglutide Injection for the indication of weight management. At present, the indication of weight management of the product has not been approved for marketing in China. The Group is the first enterprise in China to obtain clinical approval for this biosimilar.

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) analogue, which can imitate GLP-1 in human body to provide physiological functions such as dietary desire and heat intake adjustment, so as to achieve weight management. It is an ideal drug for weight management because of its cardiovascular benefits and improvement of non-alcoholic steatohepatitis, as well as its better weight loss with no risk of hypoglycemia with only one injection per week. The approval marks that the Group is authorised to commence clinical trial for the second indication of the Semaglutide Injection after that it is authorized to carry out the clinical trial for diabetes indication on 25 October 2022.

In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 19 April 2023

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon and Prof. Song Ming as independent non-executive directors.